Core Viewpoint - Jinling Pharmaceutical announced that its subsidiary, Fuzhou Meifeng Pharmaceutical Factory, received a drug re-registration approval notice from the Fujian Provincial Drug Administration for hydrolyzed protein injection, which is used for severe amino acid deficiency due to serious surgical trauma and large-area burns, as well as low protein levels caused by various diseases [2] Summary by Relevant Sections - **Product Approval** - The drug hydrolyzed protein injection is aimed at treating severe amino acid deficiency and low protein levels [2] - The approval notice will facilitate the resumption of normal production and sales of the drug [2] - **Production Resumption Requirements** - Due to a long period of non-production, the company must apply for on-site inspections from provincial drug supervision authorities and ensure that three batches of products pass inspection before the drug can be marketed [2] - **Impact on Financial Performance** - The approval is expected to benefit the drug's production and sales but will not have a significant impact on the company's recent operating performance [2]

受理号：CYHZ2514512 闽 药品名称：水解蛋白注射液 证券代码：000919 证券简称：金陵药业 公告编号：2025-057 金陵药业股份有限公司 关于分公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 金陵药业股份有限公司（以下简称"公司"）分公司金陵药业股 份有限公司福州梅峰制药厂于近日收到福建省药品监督管理局下发 的药品再注册批准通知书（2025R079210），现将相关情况公告如下： 一、申请注册药品的基本情况 二、水解蛋白注射液的相关情况 水解蛋白注射液为水解物酪蛋白和乳蛋白与山梨醇的灭菌溶液， 主要用于手术严重创伤、大面积烧伤引起的严重氨基酸缺乏，以及各 种疾病引起的低蛋白血症。 三、对公司的影响及风险提示 本次公司分公司获得《药品再注册批准通知书》，将有利于上述 药品恢复正常生产和销售，但不会对公司近期经营业绩产生重大影响。 公司将严格按照要求开展相关后续工作，实现该产品上市销售。由于 药品的生产、销售受国家政策、市场环境等因素影响，具有一定的不 确定性，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 ...

Group 1 - The company has approved the liquidation and deregistration of the Nanjing New Industry Medical Investment Fund Partnership, which will distribute the remaining assets according to the partners' paid-in capital ratio [1] - The fund has obtained the registration notice from the Nanjing Yuhuatai District Administrative Service Management Office, completing the deregistration process [1] - The fund will no longer be included in the company's consolidated financial statements [1] Group 2 - The liquidation of the fund will not adversely affect the company's overall business development or profitability, and there is no harm to the interests of the company and all shareholders [2]

本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、清算注销暨关联交易概述 金陵药业股份有限公司（以下简称"公司"）分别于 2025 年 1 月 一次临时股东大会，审议通过了《关于南京新工医疗产业投资基金合 伙企业（有限合伙）拟清算注销暨关联交易的议案》，同意对南京新 工医疗产业投资基金合伙企业（有限合伙）（以下简称"基金"）进 行清算注销，并按基金合伙人实缴出资比例分配基金剩余财产。同时， 股东大会授权经理层办理与本次基金拟清算注销相关的具体事宜。具 体内容详见公司于 2025 年 1 月 21 日在《中国证券报》《证券时报》 《上海证券报》和巨潮资讯网披露的《关于南京新工医疗产业投资基 金合伙企业（有限合伙）拟清算注销暨关联交易的公告》 （公告编号： 二、清算注销进展情况 近日，基金取得了南京市雨花台区政务服务管理办公室出具的 《登记通知书》（（320101142005）登字〔2025〕第 08140025 号）， 准予基金进行注销登记。至此，基金清算注销的工商登记手续已办理 完毕，不再纳入公司合并报表范围。 证券代码：000919 证券简称：金陵药业 公 ...

一、清算注销暨关联交易概述 证券代码：000919 证券简称：金陵药业 公告编号：2025-056 金陵药业股份有限公司 关于南京新工医疗产业投资基金合伙企业（有限合伙）拟 清算注销暨关联交易的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 三、对公司的影响 本次基金清算注销事项不会对公司整体业务发展及盈利水平产 生不利影响，不存在损害公司及全体股东利益的情形。 四、备查文件 1、《登记通知书》（（320101142005）登字〔2025〕第 08140025 号） 特此公告。 金陵药业股份有限公司董事会 2025 年 8 月 15 日 金陵药业股份有限公司（以下简称"公司"）分别于 2025 年 1 月 17 日、2025 年 2 月 7 日召开第九届董事会第十五次会议和 2025 年第 一次临时股东大会，审议通过了《关于南京新工医疗产业投资基金合 伙企业（有限合伙）拟清算注销暨关联交易的议案》，同意对南京新 工医疗产业投资基金合伙企业（有限合伙）（以下简称"基金"）进 行清算注销，并按基金合伙人实缴出资比例分配基金剩余财产。同时， 股东大会授权经 ...

Core Points - The second extraordinary general meeting of shareholders for 2025 was held on August 8, 2025, with no resolutions being rejected [1][2] - The meeting was conducted in compliance with relevant laws and regulations, ensuring the legitimacy of the proceedings and participants [3][17] Group 1: Meeting Details - The meeting took place at the company's headquarters in Nanjing, combining on-site and online voting methods [3][4] - A total of 200 shareholders attended, representing 302,220,749 shares, which is 48.4554% of the total voting shares [4][5] Group 2: Voting Results - The first resolution regarding the repurchase and cancellation of restricted stock received 99.8798% approval from attending shareholders [8][9] - The second resolution concerning changes to registered capital and amendments to the Articles of Association was approved with 99.8774% [11][12] - The third resolution for the appointment of additional non-independent directors was passed with 99.6078% support [14][15] Group 3: Legal Opinions - The legal opinion from Jiangsu Taihe Law Firm confirmed that the meeting's procedures and voting results were lawful and valid [17] Group 4: Stock Repurchase Announcement - The company announced a stock repurchase plan involving the cancellation of 178,410 shares due to non-compliance with the incentive plan [22] - The total repurchase cost was 6,075,789 yuan, funded by the company's own resources, resulting in a reduction of registered capital from 623,708,628 yuan to 621,924,528 yuan [22][24]

Group 1 - The company Jinling Pharmaceutical announced the convening of its second extraordinary general meeting of shareholders for 2025 on August 8, 2025 [2] - The meeting approved multiple proposals, including the proposal to add non-independent directors [2]

Core Viewpoint - The legal opinion letter confirms that the procedures for convening and holding the 2025 Second Extraordinary General Meeting of Jinling Pharmaceutical Co., Ltd. comply with relevant laws and regulations, ensuring the legitimacy of the meeting and its outcomes [2][5][9]. Group 1: Meeting Procedures - The meeting was convened in accordance with the provisions of the Company Law, the Shareholders' Meeting Rules, and the Company's Articles of Association [2][4]. - The notice for the meeting was published on the official website and included details such as time, location, and voting methods [3]. - The meeting utilized a combination of on-site and online voting, with specific time frames for online participation [3][4]. Group 2: Attendance and Qualifications - A total of 4 shareholders and their proxies attended the on-site meeting, along with company directors, supervisors, and senior management [4]. - 196 shareholders participated in the online voting, representing 42,767,369 shares, which is 6.8569% of the total shares [4]. - The qualifications of all attendees and the meeting conveners were verified and deemed valid [4][6]. Group 3: Voting Procedures and Results - The voting was conducted through a combination of on-site and online methods, with results announced immediately after the voting concluded [6][9]. - The proposal for the issuance of restricted stock received 99.8798% approval from the total voting rights represented at the meeting [6]. - The voting results for small shareholders showed a 99.1518% approval rate for the same proposal [6][7]. Group 4: Conclusion - The legal opinion concludes that the meeting's convening, attendance, and voting procedures were all in compliance with applicable laws and regulations, affirming the legitimacy of the meeting and its resolutions [9][10].

金陵药业股份有限公司章程 （1998 年 9 月实施；2003 年 6 月第一次修订；2004 年 12 月第二次 修订；2005 年 5 月第三次修订；2006 年 4 月第四次修订；2007 年 8 月第五次修订；2008 年 6 月第六次修订；2009 年 2 月第七次修订； 2010 年 5 月第八次修订；2012 年 8 月第九次修订；2014 年 6 月第十 次修订；2017 年 12 月第十一次修订；2018 年 5 月第十二次修订；2020 年 6 月第十三次修订；2020 年 12 月第十四次修订；2021 年 11 月第 十五次修订；2022 年 1 月第十六次修订；2022 年 3 月第十七次修订； 2022 年 6 月第十八次修订；2023 年 2 月第十九次修订；2024 年 4 月 第二十次修订;2025 年 8 月第二十一次修订） 第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组 织和行为，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限 ...

证券代码：000919 证券简称：金陵药业 公告编号：2025-055 金陵药业股份有限公司关于 回购注销限制性股票减少注册资本 股票数量合计为 178.41 万股。本次回购注销首次授予限制性股票的 价格为 3.29 元/股，回购注销预留授予限制性股票的价格为 4.29 元/ 股，回购价款总计 6,075,789 元，资金来源为自有资金。本次回购注 销完成后，公司股份总数将由623,708,628股减少至621,924,528股， 公司注册资本也将由 623,708,628 元减少至 621,924,528 元。具体内 容详见《金陵药业股份有限公司关于调整 2021 年限制性股票激励计 划回购价格及回购注销激励对象已获授但尚未解除限售的限制性股 票的公告》（公告编号：2025-049）。 二、需债权人知晓的相关信息 由于公司本次回购注销限制性股票将导致注册资本减少，根据 《中华人民共和国公司法》（以下简称"《公司法》"）等相关法律、 法规的规定，公司特此通知债权人，债权人自接到公司通知之日起 30 日内、未接到通知的自本公告披露之日起 45 日内，有权要求本公 司清偿债务或者提供相应的担保。债权人未在规定期限 ...